FDA

Non-alcoholic fatty liver disease
#FDA #Liver disease #Madrigal Pharmaceuticals #Priority Review

First drug for NASH with liver fibrosis submitted to FDA

Madrigal Pharmaceuticals has submitted an application for resmetirom, a drug for nonalcoholic steatohepatitis (NASH) with liver fibrosis, to the US Food and Drug Administration (FDA) and has requested a priority review. Resmetirom is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of… Read More

#News #Regulatory

FDA
#Drug approvals #FDA #Marketing approval authorisation #Regulatory #United States

The regulatory round-up: Five important FDA approvals

The US Food and Drug Administration (FDA) has granted marketing authorisations to several new therapeutics over the last month that will have a significant impact on areas of unmet need and the evolution of future treatments. Elevidys, Sarepta Therapeutics Elevidys became the first gene therapy for Duchenne muscular dystrophy (DMD)… Read More

#News #Regulatory

Baby on a respirator - RSV
#AstraZeneca #FDA #Monoclonal antibodies #Paediatrics #Respiratory syncytial virus

Monoclonal antibody to prevent RSV in babies approved in US

The US Food and Drug Administration (FDA) has approved AstraZeneca’s Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season. The drug is also approved in children up to 24 months of age who… Read More

#News #Regulatory

Doctor writing a prescription
#Drug repurposing #EMA #FDA #MHRA #Regulatory #Unlicensed drug

Unlicensed and off-label drugs: What do we know?

Following the death of a cancer patient after they were given an unlicensed drug, Diana Spencer unpacks the practice of prescribing unlicensed and off-label medicines. This month, a cancer patient died and three others were hospitalised in the UK after they were administered an unlicensed version of the chemotherapy drug… Read More

#Exclusive Content #Regulatory

#AMR #Covid-19 #Diabetes #Drug development #FDA #Genetics / genomics #Influenza #Parasitic disease

New DDW Highlights podcast: 10 July 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  It’s been a fascinating week in drug discovery, as AstraZeneca announced that its Phase III trial… Read More

#News

#AMR #Covid-19 #Diabetes #Drug development #FDA #Genetics / genomics #Influenza #Parasitic disease

This week in drug discovery (3-7 July)  

News round-up for 3-7 July by DDW Digital Content Editor Diana Spencer. It’s been a fascinating week in drug discovery, as AstraZeneca announced that its Phase III trial of datopotamab deruxtecan did not meet its second primary endpoint and saw an 8% drop in its stock… Read More

#News

Woman uses Digital Glucose meter
#allogeneic cell therapies #Cell and gene therapy #Diabetes #FDA #Type 1 diabetes

FDA approves first cellular therapy for type 1 diabetes

The US Food and Drug Administration has approved CellTrans’ Lantidra, the first allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells for the treatment of type 1 diabetes. Lantidra is approved for the treatment of adults with type 1 diabetes who are unable… Read More

#News #Trending News

#BioMarin Pharmaceuticals #Cell and gene therapy #FDA #Gene therapy #Haemophilia

One-time gene therapy for haemophilia A gets FDA green light

The US Food and Drug Administration (FDA) has approved the first gene therapy for adults with severe haemophilia A. BioMarin’s Roctavian (valoctocogene roxaparvovec-rvox) has been approved for the treatment of adults with severe haemophilia A (congenital factor VIII (FVIII) deficiency with FVIII activity < 1 IU/dL) without antibodies to adeno-associated… Read More

#News #Regulatory #Trending News

Neurons in a brain with Alzheimer's disease
#AC Immune #Alzheimer's #FDA #Immunotherapy #Neurodegenerative disorders

FDA fast-tracks immunotherapy for Alzheimer’s disease

AC Immune has received Fast Track designation from the US Food and Drug Administration (FDA) for its anti-amyloid beta (Abeta) active immunotherapy (vaccine)-candidate, ACI-24.060, for treatment of Alzheimer’s disease (AD). This follows FDA clearance of the Investigational New Drug (IND) application enabling expansion to the USA of the ongoing Phase… Read More

#Editor's Choice #News #Regulatory

chronic obstructive pulmonary disease
#Approvals #Chronic obstructive pulmonary disease (COPD) #Drug approvals #FDA #Verona Pharma

Verona Pharma submits COPD drug ensifentrine for US FDA approval 

Verona Pharma has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for approval of ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).  Ensifentrine is a selective dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and non-steroidal… Read More

#News #Regulatory

Magic mushrooms
#Clinical trial design #Clinical trials #FDA #Psychedelics

FDA recommendations to inform psychedelic drug development

The US Food and Drug Administration (FDA) has published new draft guidance to highlight fundamental considerations to researchers investigating the use of psychedelic drugs for the potential treatment of medical conditions, including psychiatric or substance use disorders. This is the first FDA draft guidance that presents considerations to industry for… Read More

#News #Regulatory

#Advanced Therapy Medicinal Products (ATMPs) #Cell and gene therapy #Drug development #FDA #Gene therapy

New podcast episode: DDW Highlights 26 June 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Advanced Therapy Medicinal Products (ATMPs) have been making the news this week. Particularly noteworthy have been… Read More

#News

#Advanced Therapy Medicinal Products (ATMPs) #Cell and gene therapy #Drug development #FDA #Gene therapy

This week in drug discovery (19-23 June)  

News round-up for 19-23 June by DDW Digital Content Editor Diana Spencer. Advanced Therapy Medicinal Products (ATMPs) have been making the news this week. Particularly noteworthy have been the announcement of the FDA’s approval of the first gene therapy for Duchenne muscular dystrophy, and a caution… Read More

#News

Subcutaneous injection
#Antibody #Autoimmune disease #Drug delivery #FDA #Halozyme #Phase III trial

FDA approves subcutaneous injectable for myasthenia gravis

The US Food and Drug Administration (FDA) has given approval to Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection with Enhanze for subcutaneous (SC) use for the treatment of generalised myasthenia gravis (gMG). The treatment is approved in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. Vyvgart Hytrulo is a… Read More

#News #Regulatory

#Biopharma #Cell line development #Cell lines #FDA #Genetic diseases #Genetics #R&D

New podcast: Challenges and tactics for drug development

This is the latest episode of the free DDW narrated podcast, “Challenges and tactics for transformative drug development”. It covers two articles written for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Balancing speed and quality in CLD for faster drug development”, and… Read More

#News

#AstraZeneca #Drug development #FDA #GSK #HER2 #National Institute for Health and Care Excellence (NICE) #Pfizer #Regulatory

New episode: DDW Highlights 19 June

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Regulatory approvals and industry guidelines are key to the continued development and discovery of drugs,… Read More

#News